Our Impact Delivering enduring patient impact around the world 2025
About CSL 1 14 Supporting Healthier Communities Advancing Science and Medicine for All 18 Delivering Lifesaving & Life Changing Medicines 4 From our CEO 3 22 A Positive Legacy in Local Communities Contents i Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Healthier Communities Science and Medicine Legacy
About CSL We continuously innovate to develop and deliver medicines to protect, improve and save lives around the world. We deliver our portfolio of lifesaving medicines through our three businesses: CSL Behring, CSL Seqirus and CSL Vifor. 1 Limited Our Impact 2025 From our CEO Lifesaving Medicines Healthier Communities Science and Medicine Legacy About CSL
~$6m average in economic activity per donor centre – driven by donor payments, employee wages and local community spending This Impact Report highlights our work in financial year 2025 (FY2025) to create lifesaving medicines, safeguard public health, advance science and contribute positively to the communities where we live and work. Note The 2025 financial year is from 1 July 2024 – 30 June 2025. All financial figures are reported in USD unless otherwise indicated. Disclaimer This Impact Report is produced by CSL Limited (ACN 051 588 348) for general information purposes only. While effort has been made to ensure the accuracy and completeness of the information at the time of publication, CSL makes no representations or warranties of any kind, express or implied, about the content’s accuracy, reliability, or suitability. All content is the property of CSL or its licensors and is protected by applicable intellectual property laws. Reproduction is permitted only for personal, non-commercial use and must retain all proprietary notices. Some statements about products, registered product indications or procedures may differ in certain countries. Therefore, always consult the country‑specific product information, package leaflets or instructions for use. For more information, please contact a local CSL representative. Brand names designated by a ® or a ™ throughout this publication are trademarks either owned by and/or licensed to CSL or its affiliates. Not all brands mentioned are used or registered as trademarks in all countries served by CSL. Our Impact $350k to humanitarian aid 2 Limited Our Impact 2025 From our CEO Lifesaving Medicines Healthier Communities Science and Medicine Legacy About CSL 8.8m patients treated with plasma-derived and recombinant therapies 56 new product registrations and indications in FY2025 providing more treatment options to patients with serious diseases >101m seasonal flu vaccines distributed globally 59 clinical trials underway (across clinical, registration and post launch) to find solutions to unmet needs $24m contributed to support patient communities $1m in contributions to local communities $10.3m contributed to science and innovation to advance knowledge, research and careers in biomedicine
From our CEO At CSL, our commitment to making a positive impact is rooted in our ambition to deliver enduring patient impact around the world. Our work is grounded in science but is fundamentally about people. Patients whose lives are profoundly impacted by rare and serious diseases. Vulnerable members of the community for whom influenza could be life-threatening. And those with conditions where there are currently no treatments available. Meeting the needs of patients and communities is the reason we exist – from developing new, innovative therapies for diseases to enabling greater access to life-saving vaccines. We invest significantly in medical research partnerships and collaborate with leading scientists, universities, and innovators to drive advancements in biotechnology that benefit patients worldwide. We understand that diseases impact not only the patient but their loved ones and the communities that support them. We work to build support systems to empower communities through advocacy and community outreach programs, including our Junior National Championship in the U.S., a national sports competition designed specifically for children with bleeding disorders. People are the driving force behind our work – our donors, who make vital therapies possible; our clinical trial participants, whose involvement is essential to advancing research and enabling new treatments for patients around the world; and our passionate, highly skilled employees, whose contributions extend our impact beyond medicines by creating opportunities and solutions for the communities we serve. This Impact Report highlights our work to create lifesaving medicines, safeguard public health, advance science and contribute positively to the communities where we live and work. Together, these efforts reflect the core values of CSL and build a legacy of health and hope, delivering enduring patient impact around the world. Dr Paul McKenzie, Chief Executive Officer and Managing Director, CSL Limited Our CEO Paul McKenzie donating plasma (right) and at the Junior National Championships (left). 3 Limited Our Impact 2025 About CSL Lifesaving Medicines Healthier Communities Science and Medicine Legacy From our CEO
Delivering Lifesaving & Life Changing Medicines Emma and her daughter Isabella. Isabella was born with kidney failure. We hear directly from patients and their families about the life-changing impact of receiving the right medicine. Many patients live with conditions that place a significant physical and emotional burden on their daily lives. Our role is to develop and deliver medicines that help people with serious and life-threatening conditions live fuller, more empowered lives. 4 Limited Our Impact 2025 About CSL From our CEO Healthier Communities Science and Medicine Legacy Lifesaving Medicines
4.5m people received other plasma-based products to help treat sepsis, cirrhosis, hypoalbuminemia and a range of other conditions 1.3m pregnant women treated for rhesus incompatibility 7.8k people with functional protein disorders (including hereditary angioedema and alpha-1 antitrypsin deficiency) 165k people with autoimmune diseases and immune deficiencies 6.6k people with haemophilia A & B Logan. Lives with Haemophilia B. Treatments for Serious and Rare Diseases We deliver plasma-derived and recombinant therapies for people living with serious and rare conditions including: • Hereditary bleeding disorders such as haemophilia, fibrinogen deficiency and von Willebrand disease • Immune deficiencies and autoimmune conditions such as chronic inflammatory demyelinating polyneuropathy, Guillain‑Barré syndrome, Kawasaki disease, rhesus incompatibility, primary immunodeficiency and secondary immunodeficiency • Other genetic conditions such as hereditary angioedema (HAE) and alpha‑1 antitrypsin deficiency (AATD) In FY2025, our medicines treated: 5 Limited Our Impact 2025 About CSL From our CEO Healthier Communities Science and Medicine Legacy Lifesaving Medicines
CLAUDE’S STORY Meet donor Claude Farmer Claude Farmer is a donor at CSL Plasma in Medford, Oregon, and has been donating plasma since 2010: “I feel delighted that I can do something beneficial to myself and also to someone in need… it is good to give back to those in need, those who may not have exactly what they need from their own body. “It also helps me financially, helps to have a little extra saved up and is a way to do more for my friends and family.” Plasma Donor Partners Plasma donors are the lifeblood of CSL. Without their generous commitment, we simply could not develop life-saving therapies for patients. In addition to financial compensation, we support donors’ holistic wellbeing and invest in the health equity of donor communities. We are also working to improve the experience for donors by using new technology to design individualised donations based on height, weight and hematocrit (proportion of red blood cells in a person’s blood), and introducing a range of initiatives to reduce the time it takes to donate. For example, we have introduced more than 200 new plasmapheresis machines (known as Rika) which has reduced the average overall donation time from 90–120 minutes to 60–80 minutes. Economic ripple effects A source of life-saving plasma, our donor centres also deliver economic benefits within local communities. We have close to 330 plasma centres based across the U.S., Germany and Hungary. Each year, we generate an average of $6 million in economic activity per donor centre, creating durable impact in our communities – driven by donor payments, employee wages and local community spending. In the U.S., for example, a typical donor centre employs approximately 50 full‑time equivalent (FTE) staff and pays around $2 million annually in direct wages. 6 Limited Our Impact 2025 About CSL From our CEO Healthier Communities Science and Medicine Legacy Lifesaving Medicines
The Vital Role of Our Plasma Donors We could not create lifesaving medicines without the support of our plasma donors. Many plasma donations are needed to deliver plasma-derived therapies: 900 plasma donations to treat one person with alpha‑1 antitrypsin deficiency for one year 130 plasma donations to treat one person with primary immunodeficiency for one year 1,000 plasma donations to treat one person with hereditary angioedema (HAE) for one year 1,200 plasma donations to treat one person with severe haemophilia for one year Making Clinical Trials More Bear-able We are using interactive teddy bears called “Clinical Companions” with young participants in a clinical trial for hereditary angioedema (HAE). The bears, designed by Empath Labs, are equipped with an app to simulate medical procedures, helping children better understand and emotionally engage with their treatment, making the trial experience more comforting and less stressful. Partnering with the World Federation of Haemophilia During the 2024 calendar year, we donated >100 million international units (IUs) of coagulation factor therapy to the World Federation of Hemophilia (WFH) Humanitarian Aid Program. The Humanitarian Aid Program supports developing countries by providing them with product donations, education, and training to help countries improve inherited bleeding disorders care. The donation included therapies manufactured solely to be donated, which means it will have a longer shelf life and can help give patients consistent, reliable access to the treatments they need to prevent bleeding episodes. Three-year old Koylubaev, who lives with Haemophilia A, is pictured with his father at the National Center for Maternal and Child Health in Bishkek, Kyrgyzstan. 7 Limited Our Impact 2025 About CSL From our CEO Healthier Communities Science and Medicine Legacy Lifesaving Medicines
JACK’S STORY Life with Hereditary Angioedema (HAE) “I think more than 20 or 30 times I’ve been to hospital because of my HAE. I was diagnosed with HAE when I was four years old. That’s when I had my first attack. I don’t really have any full memories of the first time that it happened other than I remember being upset because I couldn’t play on my DS because I couldn’t move my fingers! But I don’t even remember going to see all the doctors or anything – I just remember the first attack and that’s it. It was in my hand and foot at the same time and I really had no idea what was going on so it was sort of scary. It took 13 different doctors to figure out what I had. Most of my attacks were in my extremities – my hands, my feet and my face. It’s hard to move your fingers and it sort of just feels like pins and needles all the time, and in the feet it’s hard to walk on them. And as far as the facial ones, sometimes it’s hard to speak depending on where they are. When I started going through puberty the attacks became more frequent and worse. I missed 40 or 50 days of school in 7th grade. So my first throat attack, throat swell, was in the summer going into 8th grade and I was downstairs playing my Xbox and I got this weird feeling in my throat. It started to worsen within 5 minutes, and I remember I went upstairs and told my mom and she was really calm about it but I was scared because I’d never had one. “I think more than 20 or 30 times I’ve been to hospital because of my HAE.” The drive to the hospital was probably less than 15 minutes but it was the longest 15 minutes of my life. I was scared of dying. I didn’t want to die from something so instant and little that I really had no control over. Emotionally it took a toll on me. And I was never the same for a year and a half, maybe two years after, all the time being paranoid something bad might happen to me. I was having to go to therapy to get over it, because I couldn’t be somewhere where there wasn’t someone who could do my medicine. The only person I really trusted to do it was my mom so basically the whole summer I stayed at work with my mom so I was missing out on a lot. I felt isolated not only from my friends but everyone else. It was hard for me to go back to just being a normal kid.“ 8 Limited Our Impact 2025 About CSL From our CEO Healthier Communities Science and Medicine Legacy Lifesaving Medicines
Treatments for Kidney Disease People living with chronic kidney disease face a long and difficult journey associated with multiple and varying conditions and complications that severely impact their quality of life and life expectancy. We have developed a broad range of therapies and medicines to preserve renal function, manage complications and improve patients’ quality of life with kidney disease – from early stages through to late stage and dialysis. 184,000 patients treated globally for diseases associated with kidney disease such as hyperphosphatemia and hyperkalemia An abnormal elevation of phosphorus levels – hyperphosphatemia – in the blood, is a common and serious condition in chronic kidney disease patients on dialysis, because, due to severe impairment, kidneys cannot remove extra phosphorus, which can pose significant health risks, including mineral and bone disorder. Hyperkalaemia is defined as abnormally elevated levels of potassium in the blood, a serious condition in cardio-renal patients that can be responsible for cardiac arrhythmias leading to cardiac arrest and death. 11,000 patients treated globally for chronic kidney disease‑associated pruritus across the U.S., Europe and Australia This is a condition characterised by severe itching in patients with chronic kidney disease, particularly in advanced stages. In FY2025, our medicines treated approximately: 1,400 patients treated with our recently approved therapy for IgA nephropathy (Berger’s disease) in Europe in only a few months This is kidney disease caused by deposits of the protein immunoglobulin A (IgA) in the kidneys. This leads to inflammation that can impair the kidneys’ ability to filter waste from the blood. 10,000 patients treated globally (excluding the U.S.) for ANCA‑associated vasculitis Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is a systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney as the major target, and is fatal if not treated. 9 Limited Our Impact 2025 About CSL From our CEO Healthier Communities Science and Medicine Legacy Lifesaving Medicines
DANIEL’S STORY Living with Chronic Kidney Disease “It was 1993, my first year at university. Life had just begun, and I was ready to start discovering what it was all about. I was often very thirsty – but didn’t think much of it. One day, I noticed my ankle was swollen. It wasn’t painful, just a mild sprain perhaps, but I decided to go to the hospital to get it checked. The diagnosis was a total shock: my kidneys were damaged. Being diagnosed with chronic kidney disease meant my life would depend on being hooked up to a machine every second day. Nothing could have prepared me for what felt like a life sentence. I didn’t know what it meant to be “normal” anymore. Over the years, I have learned that my disease does not define me. The only time I feel like a kidney patient is during hemodialysis sessions. When I finish my treatment, I am just like everyone else: someone with dreams, hobbies and aspirations. I aim to live a fulfilling life, as any healthy person would. I try to be active both physically and mentally, to be on the move and go places. “Over the years, I have learned that my disease does not define me.” More than anything, I value my independence and being able to realise my dreams, like travel and discovering other cultures. It’s true that I depend on a machine to survive, but this machine is available all over the world. If it’s there, I will find it! So far I’ve been to India, the Philippines, Indonesia, Japan and Thailand… who knows where life will take me next? It’s my goal to find out what’s beyond the horizon!” 10 Limited Our Impact 2025 About CSL From our CEO Healthier Communities Science and Medicine Legacy Lifesaving Medicines
Support for Patients with End-Stage Renal Disease in Guatemala Delivering enduring patient impact takes many forms for our employees. For three members of the CSL Vifor team in the U.S., it meant a week-long volunteer trip to Guatemala. They helped the families of two boys with end‑stage renal disease by constructing purpose-built peritoneal dialysis rooms in their homes. Run by the charity Bridge of Life, the program’s goals are to reduce travel time and expense for families, increase work and education opportunities for caretakers and Early Access Programs: Delivering Hope Where It’s Needed Most For patients facing serious conditions with limited treatment options, time is critical. With our ambition to deliver enduring patient impact, our early access programs are designed to help patients who have exhausted all available treatment options by providing life-changing medicines as early as possible, before they’re commercially available. Over1,000 patients worldwide have been helped to access approved treatments (before they are commercially available) for conditions such as IgA nephropathy (Berger’s Disease), chronic kidney disease-associated pruritus, hyperkalemia and ANCA‑associated vasculitis CSL employees volunteering in Guatemala. “ The trip to Guatemala was profoundly life changing. It directly benefited two local families by providing access to a dialysis room and securing essential medical care. Additionally, it offered the volunteers a deep insight into the challenges others face in obtaining medical treatment. This unique opportunity has undoubtedly enriched us as individuals.” Carlos Flores, one of the volunteers Constructing a peritoneal dialysis room in Guatemala. the patients themselves, increase compliance with at-home peritoneal dialysis rooms, and to create a path to eligibility for kidney transplant among these young patients. The CSL volunteers started their build with a frame installed before they arrived, and added walls, a roof, then plastered and painted outside. Inside, they painted walls to match the two boys’ interests, including cartoon shows and soccer. The volunteers also used the donations from their CSL colleagues to bring the families toys, books, clothes, and cleaning supplies, as well as creating a fund to assist paediatric patients in financial need. 11 Limited Our Impact 2025 About CSL From our CEO Healthier Communities Science and Medicine Legacy Lifesaving Medicines
Improving Blood Health, Globally Patient blood management practice addresses the relationship between iron deficiency, anaemia and surgery – a time when blood loss must be managed carefully. Having anaemia prior to surgery is associated with increases in mortality, surgical complications, the need for blood transfusions and longer hospital stay.1 As a member of the Blood & Beyond initiative, we’re working with governments and hospitals to enhance patient outcomes through advocating for patient blood management – an approach focused on managing and preserving a patient’s own blood. The benefits include: • diagnosing and appropriately correcting anaemia and iron deficiency, • minimising blood loss and bleeding, and • supporting patients with appropriate treatment instead of reverting to blood transfusion. Implementing one patient blood management program led to a 28% reduction in mortality, a 21% reduction in infection, and a 15% reduction in time spent in hospital.2 Through the Blood & Beyond initiative, we advocate for patient blood management by raising awareness of its enduring benefits and publishing scientific materials aimed at helping hospitals to implement these practices. Treatments for Iron Deficiency Iron is needed for the proper functioning of many systems in the human body, including the heart, muscles and red blood cells. It also plays a vital role in the immune system, the development of the brain and cognitive function. Iron deficiency is a very common condition. Studies show that it affects up to one third of the global population. Despite its high occurrence and its potentially serious consequences for patients’ health, iron deficiency remains an overlooked, under-diagnosed and under-treated condition. We have pioneered a range of iron-based medicines to treat iron deficiency, helping patients affected by these conditions to live better, healthier lives. >33m patient-years of our high-dose IV iron across heart failure, major elective surgery, women’s health, nephrology and gastroenterology patients >38m patient-years of our low‑dose IV iron, mainly in nephrology patients 1. Ranucci, M., Ballotta, A., La Rovere, M. T., Castelvecchio, S., & Menicanti, L. (2013). Postoperative blood transfusion and outcome in adult cardiac surgery. Annals of Thoracic Surgery, 96(2), 478–485. 2. Frank, S. M., Tran, K. M., Fleisher, L. A., & Ness, P. M. (2017). Reducing unnecessary blood transfusions: A 10-year experience. Anesthesiology, 127(4), 754–764. Pregnancy creates extra demand for certain nutrients including iron. These treatments are measured in ‘Patient-Years’ – a measurement used in epidemiology and clinical research to quantify the amount of time patients are exposed to a treatment. Since market authorisation and as of the end 2024, we delivered: 12 Limited Our Impact 2025 About CSL From our CEO Healthier Communities Science and Medicine Legacy Lifesaving Medicines
ELENA’S STORY Facing Iron Deficiency “My symptoms came on gradually. I felt exhausted all the time and I was struggling to get out of bed in the morning, despite being in a very happy period of my life. My hair was also falling out more than normal. I’m an active person – I work as a radio host, I spend time with my son, I love to go out and I keep fit in the gym. I visited several doctors and none of them were able to identify anything was out of the ordinary. They suggested my worsening symptoms were a result of stress. I felt misunderstood by everyone at that time. Something just felt off, and I knew there had to be another explanation for the way I was feeling. Eventually I went to visit a doctor who suggested we test for iron deficiency. She found that my ferritin levels were very low. My symptoms were a result of iron deficiency and I was recommended an intravenous iron infusion. “For me, the results of that first treatment were quick. I felt significantly better physically.” Having my energy back totally changed my life at that time, and I could get on with doing the things I love. I regularly go for check-ups with my doctor now, to make sure my ferritin levels are still within a healthy range. I don’t think there is enough awareness about iron deficiency and its symptoms. Now, when I talk to my friends I always suggest that they test for iron deficiency and get their ferritin levels checked. It’s so easily treatable.” 13 Limited Our Impact 2025 About CSL From our CEO Healthier Communities Science and Medicine Legacy Lifesaving Medicines
Supporting Healthier Communities We stand alongside our partners on the front line of public health, using our expertise and combined strength to protect people and communities around the world. 14 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Science and Medicine Legacy Healthier Communities
3. World Health Organization (2025) Influenza (seasonal). https://www.who.int/news-room/factsheets/detail/influenza-(seasonal) 4. Centre for Disease Control and Prevention (2025) Severity, Disease Burden, and Prevented Burden for the 2024-2025 Influenza Season https://www.cdc.gov/acip/downloads/slides-2025-06-25-26/03dugan-influenza-508.pdf 5. Centre for Disease Control and Prevention (2025) Preliminary Flu Vaccine Effectiveness (VE) Data for 2024-2025 https://www.cdc.gov/flu-vaccines-work/php/effectiveness-studies/2024-2025.html Vaccines We specialise in discovering, developing and delivering vaccines, with a focus on influenza. Seasonal influenza (the flu) is an acute respiratory infection caused by influenza viruses, common in all parts of the world.3 In the U.S. alone, the CDC estimates that influenza vaccination prevented 12 million illnesses, 5.7 million doctor visits and 240,000 hospitalisations in the 2024–25 season.4 Data from the 2024–2025 season shows the vaccine continues to offer strong protection – reducing the chance of needing medical care or being hospitalised for influenza by up to 78%, especially in children and teenagers.5 Most people who get sick with influenza will have a mild illness. However, some people – such as people over 65 years of age, young children, pregnant women and people with chronic illnesses – are more likely to get influenza complications that can result in hospitalisation and sometimes death. Our bodies and the influenza virus are in a never-ending race. As our immune system evolves to avoid infection, the virus adapts to evade our immune system. Influenza spreads best when temperatures and humidity are low, so the influenza season coincides with the winter months in all different parts of the globe. This is why we need new influenza vaccines each influenza season – and why we are always working to stay ahead of the mutating virus. >101m doses of influenza vaccines delivered in FY2025 helping prevent an estimated 15,284,430 illnesses, 220,349 hospitalisations and 37,572 deaths 15 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Science and Medicine Legacy Healthier Communities
KENNEDY’S STORY When the Flu Strikes Suddenly While it may seem unlikely, the flu can lead to severe complications even in healthy children. For two-and-a-half-year-old Kennedy Parks, a case of Influenza B led to a tragic and heartbreaking outcome. It all began with the usual symptoms of the flu: fever, fatigue and general discomfort. Kennedy’s parents, Jesse and Megan Parks, thought it was just another typical illness, not realising the gravity of the situation. “We weren’t too worried,” Megan recalls. “We thought it was just a cold or the flu.” Kennedy had been enjoying a fun day with family and friends just days before, dancing and playing during a Super Bowl party. The change in her condition was swift and alarming. When Kennedy’s breathing became laboured and her lips started turning blue, Jesse and Megan knew something was terribly wrong. Megan rushed Kennedy to Texas Children’s Hospital, keeping a watchful eye on her daughter in the rearview mirror. However, during the drive, Kennedy stopped responding. Megan pulled over and called 911, and a kind passerby helped contact her husband while emergency services were on the way. “ We didn’t realise that a flu vaccination could have protected her and significantly reduced the risk of hospitalisation or death.” Sadly, despite their swift action, Kennedy lost her battle with the flu that day. “If only we had known how serious the flu can be,” says Megan. “We didn’t realise that a flu vaccination could have protected her and significantly reduced the risk of hospitalisation or death. We found out too late.” Jesse and Megan Parks now dedicate their efforts to raising awareness about the importance of flu vaccinations, hoping to prevent other families from experiencing the same devastating loss they endured. Kennedy Parks with her parents Megan and Jesse Parks. 16 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Science and Medicine Legacy Healthier Communities
Partnering with Governments to Prepare for Future Pandemics We have long been a trusted partner for governments worldwide, helping them meet community needs and quickly respond to future pandemics or outbreaks. We are currently a pandemic and outbreak partner with over 30 governments globally. Through these partnerships, we support governments and public health agencies in the U.S., EU, UK and beyond by delivering pre-pandemic vaccines and adjuvant (substances that help vaccines work more effectively) stockpiles. As of June 2025, CSL and its predecessor companies have contributed $57.2 million to the World Health Organization’s (WHO’s) Pandemic Influenza Preparedness (PIP) Framework. PIP brings together governments, industry and the WHO to implement a global approach to pandemic influenza preparedness and response. It aims to improve the sharing of information on influenza viruses with pandemic potential and the equitable access to products necessary to respond to an influenza pandemic including vaccines, antivirals and diagnostics. Antivenoms Approximately 3,000 Australians are hospitalised due to contact with a venomous creature in Australia every year. As the only manufacturer in the world to supply antivenoms for venomous creatures native to Australia, we serve a significant public health need. We are the sole provider of a unique range of products made in the national interest for the Australian government, including antivenoms and Q fever vaccine. We also contribute to programs that help raise awareness and educate communities about venomous bites and stings in the Asia Pacific region. $57.2m contributed to the World Health Organization’s Pandemic Influenza Preparedness Framework The PNG Snakebite Partnership Papua New Guinea (PNG) has historically had one of the highest rates of snakebite death in the world. It’s estimated there are more than 1,000 deaths a year due to snakebites in PNG, with nearly half of all fatalities involving children. PNG has many of the same venomous snakes that are found in Australia. Through our partnership with the Australian government, PNG’s National Department of Health and St John Ambulance PNG, we provide an annual donation of up to 600 vials of Australian-made antivenom to PNG. St John Ambulance distributes the antivenoms to more than 65 healthcare clinics through PNG, trains healthcare workers in snakebite patient management, and collects epidemiological data to improve local snakebite care. Since 2018, the partnership has helped save over 2,500 lives, provided almost 3,500 doses of antivenoms for venomous snakes and marine creatures, and delivered training to 2,300 healthcare workers, creating an enduring patient impact. In addition to an annual financial contribution, we have also committed 10% of influenza vaccine output in real time to the WHO for deployment to lower-middle income countries in the event of a pandemic emergency. Our partnerships also extend to academic bodies like the Pandemic Institute in Liverpool. We are halfway through a five year partnership and are collaborating on projects aimed at addressing vaccine hesitancy in underserved communities, enhancing manufacturing processes, and leveraging AI to model avian influenza. These efforts are particularly crucial given the global concern about highly pathogenic avian influenza (HPAI) in wild bird populations. Improving Vaccine Effectiveness Influenza viruses constantly change through a process called antigenic drift, which allows them to evade the immune system. Occasionally, two viruses can exchange genetic material in a process called reassortment. Each year, the WHO monitors global influenza activity and recommends which influenza virus strains should be included in seasonal vaccines. For decades, we have worked with our partners in Liverpool and Melbourne on the responsible development of vaccine seed strains and reassortants, helping to ensure the effectiveness of influenza vaccines worldwide. CSL Seqirus has pioneered the use of cell-based seed strains, which avoid the changes that can occur when viruses are grown in eggs. This means vaccines are a closer match to the circulating influenza viruses, offering people greater protection, and allowing faster, more reliable vaccine production – especially important during a pandemic. St John Ambulance PNG staff following the training of healthcare workers in snakebite envenomation management. 17 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Science and Medicine Legacy Healthier Communities
Advancing Science and Medicine for All Our research and development (R&D) efforts are focused on providing better options for patients and public health. We aim to create enduring impact by helping people to lead full lives by meeting unmet medical needs, preventing infectious diseases and protecting public health through the development of new medicines and vaccines. 18 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Healthier Communities Legacy Science and Medicine
Finding New Solutions We have a strong and varied R&D pipeline, focused on five therapeutic areas: immunoglobulins, transplant and immunology, hematology, cardiovascular and renal, and vaccines. In FY2025 alone we invested $1.4 billion in R&D. During this period, we achieved 56 regulatory approvals, comprising 43 new product registrations and 13 new indications – providing more treatment options for patients with serious diseases. In FY2025, we progressed 59 clinical trials across clinical, registration and post launch stages. When we are developing new treatments, we aim to create enduring impact for patients and public health. That is why it is important that our programs are informed by patient insights and are representative of the diverse people and communities affected by these diseases and conditions. In FY2025, more than 33,000 patients participated in our clinical trials. At CSL, we are dedicated to advancing global health through groundbreaking research and innovative treatments. Each year, our scientists and medical professionals publish numerous peer-reviewed papers, contributing valuable knowledge to the medical community and beyond. In FY2025, we published over 100 manuscripts in peer-reviewed journals that adhere to the stringent standards set by the International Committee of Medical Journal Editors (ICMJE). In order to ensure the public can engage with and benefit from the latest research we routinely prepare lay language summaries of clinical studies. The information is presented in a way that is easy to understand, avoiding technical jargon. These summaries are available in multiple languages to ensure that the general public can access and understand the information. In the past year we prepared lay summaries for 10 clinical studies. Number of clinical trials underway in FY2025, across clinical, registration and post‑launch stages Immunoglobulins 8 Hematology 15 Cardiovascular and renal 12 Transplant and immunology 14 Vaccines 10 59 “ We sometimes romanticise scientific breakthroughs, imagining that they occur because of a single genius or a singular lightbulb moment. But the reality of science looks more like a constellation than one shining star. It generally takes multiple lines of inquiry and the layered accumulation of knowledge and experience – and a whole lot of perseverance.” Dr Bill Mezzanotte, Executive Vice President, Head of Research & Development, CSL $1.4b invested in R&D in FY2025 19 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Healthier Communities Legacy Science and Medicine
Working Together on Challenges We know that partnerships can accelerate innovation and delivery of new life-saving and protective medicines. We work closely with organisations that have unique technologies to address our patients’ unmet needs around the globe. Through the CSL Research Acceleration Initiative (RAI), we work with a network of over 330 research organisations across 26 countries. Through long‑term collaborations with academic scientists, the RAI promotes innovation by providing early funding and access to our R&D experts to help advance new technologies and assets towards real-world treatments. To date, the RAI has funded 38 programs. Of these, 23 have been completed – four transitioned to CSL’s research division and 19 were terminated, representing a 17% probability of success. We also form strategic partnerships with incubators, accelerators and venture funders to build the broader ecosystem. One of the biggest barriers to translating and commercialising medical research is the lack of capital and access to expertise. In FY2025, we committed $25 million in Brandon Capital’s new fund, Brandon BioCatalyst Fund 6 (BB6). With over $1 billion under management and a strong track record of successful biotech ventures, by investing in Brandon Capital’s BB6 fund we have access to a curated network of more than 50 medical research institutes, universities and hospitals across Australia and New Zealand, enhancing opportunities for cutting‑edge innovation. In October 2024, CSL became the cornerstone industry investor in Biofund IV, a dedicated healthcare fund with a European focus. Europe is a rich source of early-stage external innovation for CSL and is home to 43 of the world’s top 100 life science universities. Managed by Kurma Partners, Biofund IV has already made its first three investments and aims to support 16 to 20 companies. Like its predecessors, Biofund IV focuses on companies developing innovative therapeutics, following a balanced, risk-managed strategy that includes both company creation and investments in established venture-stage companies. The Jumar Bioincubator: Supporting Biotech Entrepreneurs Our Global Headquarters and Centre for Research & Development in Melbourne, Australia, is home to Jumar Bioincubator, a world‑class hub supporting 34 biotech companies – 28 of which are startups. Delivered in partnership with WEHI, the University of Melbourne, as well as initial investor Breakthrough Victoria and operator Cicada Innovations, Jumar delivers a wide range of services, including educational programs on commercialisation, facilitated access to investors, industry mentoring and access to specialist service providers. Jumar offers comprehensive support to biotech start-ups, supporting them to translate groundbreaking biomedical discoveries into tangible commercial outcomes. The name ‘jumar’ refers to a mountaineering technique by which climbers receive the support necessary to efficiently scale and speedily ascend challenging mountains. By providing a first home for young aspiring biotech ventures, the Jumar Bioincubator similarly aims to help biotech entrepreneurs to ascend and scale the heights of their industry. >330 research organisations in our network across 26 countries, accelerating the development and commercialisation of promising discoveries through the CSL Research Acceleration Initiative 38 programs funded under the CSL Research Acceleration Initiative Dr Christos Papadimitriou, CEO & Managing Director of Tessara Therapeutics. Residents of the Jumar Incubator, Tessara Therapeutics is developing cutting-edge ‘minibrain’ technology to accelerate research into neurodegenerative diseases. Image © City of Melbourne 2024, photography: Louis Trerise Photography PTY LTD. 20 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Healthier Communities Legacy Science and Medicine
Awards and Grants We support collaborative innovation through the endowment of awards and grants to researchers around the world. In FY2025, we contributed $10.3 million to science and innovation to advance knowledge, research and careers in biomedicine. One example is the CSL Centenary Fellowships. Since 2016, CSL has awarded two individual fellowships annually – each valued at A$1.25 million over five years – to early to mid-career medical researchers. These fellowships support discovery and translational medical research and are a key part of CSL’s commitment to fostering a thriving medical research community and advancing Australian science. Advancing Sickle Cell Disease Research Through our HemMa research collaboration in Switzerland, we’re discovering novel insights into the pathophysiology of sickle cell disease (SCD). The research – a collaboration between CSL, the Departments of Haematology of the University Hospitals of Bern and Lausanne and the University of Bern – is helping identify key biomarkers and improve understanding of SCD complications. In addition to shaping our clinical study designs for CSL889 hemopexin (a plasma-based treatment for SCD), we’re sharing the findings at conferences around the world, contributing to enduring patient impact globally. This includes at the American Society of Hematology, the European Hematology Association, and the Swiss Oncology and Hematology Congress. The research team is also preparing two manuscripts, one on transcriptomic profiling and the other on biomarker findings related to SCD. “ I lead a team of medical and scientific experts who have in-depth conversations with leading clinicians to understand how the scientific data translates into benefits for patients. This ensures that the right treatment is prescribed to the right patient at the right time. I’m really proud of the efforts that our team makes.” Claire Morgan, Senior Director, Medical Affairs, CSL Seqirus DR QI ZHANG’S STORY CSL Centenary Fellowship recipient “I’m a group leader at the South Australian Immuno Genomic Cancer Institute at the University of Adelaide. All cells in our body share identical DNA but what makes them different is sets of genes that are turned on and off in different cell types. But these processes are not fully understood. My work is going to study how the different sets of genes turn on and off in both normal development and also in cancer or other diseases. This is epigenetics. We want to know what’s happening in a healthy cell, then we want to know what is going wrong in a cancer cell – when it loses its identity. Using the CSL Centenary Fellowship we hope to have generated fundamental knowledge that researchers around the world can use to develop new drugs. It’s complex work which will use a range of approaches ranging from biochemistry, biophysics, molecular and cell biology, structural biology, genomics and bioinformatics. Here at our institute in Adelaide we will also explore the therapeutic potential of our basic research findings. It’s an exciting time to be a researcher with so many developments in technologies like RNA therapeutics and genomics. I hope that in a decade there will be many more options to fight disease.” 21 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Healthier Communities Legacy Science and Medicine
A Positive Legacy in Local Communities We actively support initiatives that improve the health or science education of the communities where we live and work, and we are there to help in times of emergency. 22 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Healthier Communities Science and Medicine Legacy
Supporting Our Communities We have contributed $24m to support patient communities and $1m to local community organisations. Many of our employees are strongly connected to the communities where they live and work. When they are inspired to contribute to important causes, we seek to support them in their endeavours. Donating flu vaccines to support Liverpool community For many years, we have donated flu vaccines from our Liverpool site in the UK to the local fire service, police service and the Whitechapel Centre for the Homeless. The Whitechapel Centre is a leading homeless and housing charity in the Liverpool region. They work with people who are rough sleeping, living in hostels or struggling to manage their accommodation. Up to $1,000 in matching donations to charities of our employees’ choice through our Workplace Giving programs in Australia and the U.S. $100 donation for every eight hours of volunteer work our employees donate to a qualifying nonprofit organisation through the Dollars for Doers Program in the U.S. Junior National Championship Created by CSL, the ‘Gettin’ in the Game’ Junior National Championship (JNC) was the first national sporting competition designed specifically for kids with bleeding disorders such as haemophilia and von Willebrand disease. The program gives children with bleeding disorders an opportunity to compete in baseball, basketball, golf or swimming and provides education and information-sharing opportunities for participants and their parents/caregivers. Since the first JNC in 2002, we have brought the competition to more than 30 towns across the United States, helping close to 1,000 competitors and their families connect with other members of the bleeding disorders community. The JNC encourages kids with bleeding disorders to stay physically active, learn more about their disease, and regularly connect with their treatment provider to effectively manage their condition. ~1,000 young competitors with bleeding disorders from more than 30 towns across the U.S. 23 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Healthier Communities Science and Medicine Legacy
• Supporting local faith-based groups to distribute toiletries to people experiencing homelessness and connect them with community health centres for free health assessments and treatment. • Collaborating with groups like the European Heart Failure Policy Network, Mechanism for Coordinated Access to Orphan Medicines (MoCA) and European Alliance for Access to Safe Medicines to help ensure patients get the care they need. CSL also took part in ten major collaborations focused on improving how medicines are developed with patients in mind. Our team played leading roles in groups like PALADIN and EUPATI, which bring together patient advocates and industry experts. CSL’s processes and materials were also recognised as examples of best practice, helping to shape how the industry involves patients in drug development. Hurricanes Helene and Milton In the aftermath of Hurricanes Helene and Milton, we donated $350,000 in direct aid to support relief efforts in the most affected communities and to match employee donations. We worked with local authorities to identify trusted and active local organisations delivering wide-ranging relief efforts. To ensure our relief and aid reaches those directly impacted as quickly as possible, we direct resources to organisations we have either partnered with in the past and have a proven track record of performance and transparency, or those endorsed by local governments and regulators. As part of these efforts, we also donated 20,000 doses of influenza vaccine by partnering with Direct Relief, a nonprofit humanitarian organisation that provides emergency medical resources and assistance to vulnerable communities in the aftermath of natural disasters. In addition to the company’s contributions, our employees donated food and other essential items to those who were impacted. Our donations included: $175k to the North Carolina Disaster Relief Fund $175k to Hope Florida Committed to Supporting Patients and Public Health We work with patient advocacy groups and public health organisations at international, regional, national and local levels to create enduring patient impact by improving access to quality care, expanding education and outreach, and promoting better health services. Examples include: • Partnering with organisations like the Jeffrey Modell Foundation, EURORDIS, and NORD to raise awareness of rare diseases – a key factor in misdiagnosis and delayed diagnosis. Once diagnosed, we offer support services and programs for our therapies. • Collaborating with Families Fighting Flu to highlight the risks of influenza. • Sponsoring community events such as Men’s Wellness Day and the Sugar Cane Festival to promote plasma donation and clinical trial participation among underserved populations. Humanitarian aid We support humanitarian aid by collaborating with local organisations that have a deep understanding of community needs, including those affected by natural disasters. We offer financial aid to humanitarian situations based on the scale of the impact; impact on our employees; presence of employees and stakeholders in affected areas; and capacity for both the country affected along with our own ability to respond. We can also respond to requests for product donations when we can meet local and/or global regulatory requirements and can source local partners to facilitate transportation safely. This includes ensuring they’re kept at the right temperature and that there are the right support systems in place on the ground. United Way Flood Relief. 24 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Healthier Communities Science and Medicine Legacy
Reducing Our Impact on the Environment We are committed to conducting our operations in a way that minimises negative impact on the environment, protects biodiversity and conserves natural resources. Here are some of the ways we’re working to reduce our greenhouse gas (GHG) emissions: • Our European manufacturing sites have been using 100% renewable purchased electricity since early 2023. • In FY2025, our Scope 1 emissions remained stable, reflecting consistent operational performance. • We continue to implement our energy efficiency and emissions reduction roadmap to support our FY2030 targets. • Our Scope 2 emissions decreased by approximately 29% compared to FY2024, primarily due to our Australian sites transitioning to renewable electricity from 1 January 2025 under a Renewable‑Linked Power Purchase Agreement. Inclusion and Belonging Our 29,000+ people are at the heart of delivering our therapies that save lives, protect public health and support the patients and communities we serve – creating enduring impact for those who rely on us. Creating a culture where everyone belongs, develops and thrives is foundational to who we are as a company and is reflected in our Values. Our workforce reflects the patients and communities we serve. Our commitment to inclusion and belonging extends beyond our front doors. It is reflected in how we engage with and support the community where we live and work. One way we contribute is by providing employment opportunities for underrepresented members of the community. For over 10 years we have partnered with Valida, a Swiss social enterprise dedicated to providing individuals who have support needs with the opportunity for equal and self-determined access to work. Valida’s team assists with the manual packaging of small‑scale quantities of our iron and nephrology therapeutics at our Swiss manufacturing site. In Australia, we joined the Australian Disability Network in 2024, along with three other major employers in Australia, to launch the Employing 100 Program. This partnership with the Australian government seeks to successfully place 100 job seekers with disability into roles across the four companies. We’ve made solid progress in building a workforce that brings a broad range of perspectives to our work. We know there’s more to do to create an inclusive culture and make a positive impact in our communities. We’re committed to that work – and proud of the contribution our employees make every day. “ It’s vital that our employees mirror the patients, donors, and people we serve – so that we bring a wide variety of viewpoints to the important decisions we make and problems we solve.” Paul McKenzie, CEO and Managing Director, CSL 25 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Healthier Communities Science and Medicine Legacy
RkJQdWJsaXNoZXIy MjE2NDg3